炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 据了解，瑞济生物于2002年成立，主营业务是生产、销售生物羊膜。主要产品和服务为凹凸羊膜产品、 生物骨科羊膜产品、湿态生物羊膜产品，属国家三类医疗器械，主要用于骨科和眼科领域，包括肌腱损 伤后的修复、眼表烧伤创伤及损害创面的修复、泪道阻塞探通后的植入和支撑等。 来源：资本秘闻 营收、净利双降之下，昊海生科（688366）拟布局生物羊膜。 昊海生科最新公告显示，经公司第六届董事会第六次会议审议通过，公司及独立第三方钟晓燕与江西瑞 济生物工程技术股份有限公司（以下简称"瑞济生物"）现有股东苗九昌、苗春云签订《股份转让框架协 议》，分别以3835.15万元、475.6万元的价格分三个阶段受让苗九昌、苗春云合计持有的瑞济生物 846.61万股、104.99万股股份。交易完成后，公司将持有瑞济生物19.8%的股份。 值得一提的是，瑞济生物原在全国中小企业股份转让系统挂牌，后经瑞济生物主动申请，于今年6月终 止挂牌。本次交易定价为4.53元/股，系以瑞济生物终止在全国中小企业股份转让系统挂牌前的市场交 易价格为基础，经各方协商一致确定。瑞济生物在终 ...

营收、净利双降之下，昊海生科（688366）拟布局生物羊膜。 昊海生科最新公告显示，经公司第六届董事会第六次会议审议通过，公司及独立第三方钟晓燕与江西瑞济生物工程技术 股份有限公司（以下简称"瑞济生物"）现有股东苗九昌、苗春云签订《股份转让框架协议》，分别以3835.15万元、 475.6万元的价格分三个阶段受让苗九昌、苗春云合计持有的瑞济生物846.61万股、104.99万股股份。交易完成后，公司 将持有瑞济生物19.8%的股份。 据了解，瑞济生物于2002年成立，主营业务是生产、销售生物羊膜。主要产品和服务为凹凸羊膜产品、生物骨科羊膜产 品、湿态生物羊膜产品，属国家三类医疗器械，主要用于骨科和眼科领域，包括肌腱损伤后的修复、眼表烧伤创伤及损 害创面的修复、泪道阻塞探通后的植入和支撑等。 值得一提的是，瑞济生物原在全国中小企业股份转让系统挂牌，后经瑞济生物主动申请，于今年6月终止挂牌。本次交 易定价为4.53元/股，系以瑞济生物终止在全国中小企业股份转让系统挂牌前的市场交易价格为基础，经各方协商一致 确定。瑞济生物在终止挂牌前最后一个交易日（2025年2月11日）的收盘价为4.81元/股。 昊海生科是一家从 ...

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has experienced a decline of 17.01% year-to-date, with a recent drop of 2.00% on November 26, 2023, indicating potential challenges in the company's market performance [1]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down 10.63% compared to the previous year [2]. - Cumulatively, the company has distributed a total of 891 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haohai Biological increased by 7.44% to 8,388, with an average of 0 circulating shares per shareholder [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 5.6048 million shares, an increase of 2.617 million shares from the previous period [3]. Market Activity - On November 26, 2023, Haohai Biological's stock traded at 49.46 yuan per share, with a total market capitalization of 11.503 billion yuan. The trading volume was 38.4425 million yuan, with a turnover rate of 0.40% [1]. - The net outflow of main funds was 1.5809 million yuan, with significant selling activity observed [1].

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has experienced a decline of 15.47% year-to-date, with a slight recovery observed on November 25, where it rose by 2.13% to reach 50.38 CNY per share, indicating potential market interest despite recent downturns [2][1]. Company Overview - Haohai Biological Technology, established on January 24, 2007, and listed on October 30, 2019, is located in Shanghai and specializes in the research, production, and sales of medical devices and pharmaceuticals [2]. - The company's revenue composition includes: 44.12% from medical beauty and wound care products, 28.18% from ophthalmic products, 17.39% from orthopedic products, 8.46% from anti-adhesion and hemostatic products, and 1.86% from other products [2]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion CNY, reflecting a year-on-year decrease of 8.47%, while the net profit attributable to shareholders was 305 million CNY, down 10.63% year-on-year [2]. - The company has distributed a total of 891 million CNY in dividends since its A-share listing, with 557 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 7.44% to 8,388, with an average of 0 shares held in circulation per shareholder [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 5.6048 million shares, an increase of 2.617 million shares compared to the previous period [3]. Market Activity - On November 25, the stock saw a trading volume of 31.1529 million CNY, with a turnover rate of 0.32%, and a net inflow of main funds amounting to 1.7261 million CNY [1].

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has shown fluctuations, with a recent increase of 2.01% on November 10, 2023, despite a year-to-date decline of 13.94% [1][2]. Company Overview - Haohai Biological Technology, established on January 24, 2007, and listed on October 30, 2019, is located in Shanghai and specializes in the research, production, and sales of medical devices and pharmaceuticals [2]. - The company's main revenue sources are: medical beauty and wound care products (44.12%), ophthalmic products (28.18%), orthopedic products (17.39%), anti-adhesion and hemostatic products (8.46%), and other products (1.86%) [2]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down 10.63% year-on-year [2]. - The company has distributed a total of 891 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 7.44% to 8,388, with an average of 0 shares per shareholder [2]. - Hong Kong Central Clearing Limited is the seventh largest circulating shareholder, holding 5.6048 million shares, an increase of 2.617 million shares from the previous period [3]. Market Activity - On November 10, 2023, the stock traded at 51.29 yuan per share, with a total market capitalization of 11.929 billion yuan and a trading volume of 28.2676 million yuan [1]. - The net inflow of main funds was 2.4664 million yuan, with large orders accounting for 20.66% of purchases and 11.93% of sales [1].